Cargando…
A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease
PURPOSE: The prediction of the loss of response (LOR) to infliximab (IFX) is crucial for optimizing treatment strategies and shifting biologics. However, a secondary LOR is difficult to predict by endoscopy due to the intestinal stricture, perforation, and fistulas. This study aimed to develop and v...
Autores principales: | Chen, Yueying, Li, Hanyang, Feng, Jing, Suo, Shiteng, Feng, Qi, Shen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238542/ https://www.ncbi.nlm.nih.gov/pubmed/34194236 http://dx.doi.org/10.2147/JIR.S314912 |
Ejemplares similares
-
MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
por: Feng, Jing, et al.
Publicado: (2022) -
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
por: Chen, Yueying, et al.
Publicado: (2021) -
Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients
por: Zhu, Chao, et al.
Publicado: (2023) -
Infliximab response associates with radiologic findings in bio-naïve Crohn’s disease
por: Yueying, Chen, et al.
Publicado: (2023) -
Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594]
por: Zhu, Chao, et al.
Publicado: (2023)